Identification of candidate nasopharyngeal carcinoma serum biomarkers by cancer cell secretome and tissue transcriptome analysis: Potential usage of cystatin A for predicting nodal stage and poor prognosis

2010 ◽  
Vol 4 (10-11) ◽  
pp. 857-857
Author(s):  
Kai-Ping Chang ◽  
Chih-Ching Wu ◽  
Hua-Chien Chen ◽  
Shu-Jen Chen ◽  
Pei-Hua Peng ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Cancer Cell ◽  
Transcriptome Analysis ◽  
Poor Prognosis ◽  
Serum Biomarkers ◽  
Nodal Stage ◽  
Cystatin A

Identification of candidate nasopharyngeal carcinoma serum biomarkers by cancer cell secretome and tissue transcriptome analysis: Potential usage of cystatin A for predicting nodal stage and poor prognosis

PROTEOMICS ◽  
2010 ◽  
Vol 10 (14) ◽  
pp. 2644-2660 ◽  
Author(s):  
Kai-Ping Chang ◽  
Chih-Ching Wu ◽  
Hua-Chien Chen ◽  
Shu-Jen Chen ◽  
Pei-Hua Peng ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Cancer Cell ◽  
Transcriptome Analysis ◽  
Poor Prognosis ◽  
Serum Biomarkers ◽  
Nodal Stage ◽  
Cystatin A

scholarly journals Increased Serum Levels of Macrophage Inflammatory Protein-3α and Cystatin A Predict a Poor Prognosis of Nasopharyngeal Carcinoma

Medicine ◽  
2014 ◽  
Vol 93 (22) ◽  
pp. e123 ◽  
Author(s):  
Yonglin Cai ◽  
Jun Li ◽  
Aiying Lu ◽  
Weiming Zhong ◽  
Jianquan Gao ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Poor Prognosis ◽  
Serum Levels ◽  
Inflammatory Protein ◽  
Cystatin A ◽  
Macrophage Inflammatory Protein

Overexpression of HP1γ is associated with poor prognosis in non-small cell lung cancer cell through promoting cell survival

Tumor Biology ◽  
2014 ◽  
Vol 35 (10) ◽  
pp. 9777-9785 ◽  
Author(s):  
Ji Zhou ◽  
Hui Bi ◽  
Ping Zhan ◽  
Cunjie Chang ◽  
Chunhua Xu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Survival ◽  
Cancer Cell ◽  
Cell Lung Cancer ◽  
Poor Prognosis ◽  
Small Cell ◽  
Lung Cancer Cell ◽  
Small Cell Lung

Maintenance intervention to improve survival in patients with metastatic nasopharyngeal carcinoma who benefit from first-line treatment: A prospective multicenter randomized controlled clinical study.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 6035-6035
Author(s):  
Ying Lu ◽  
Haixin Huang ◽  
Hui Yang ◽  
Xiaohua Hu ◽  
Xianbing Feng ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Maintenance Therapy ◽  
Poor Prognosis ◽  
Observation Group ◽  
First Line ◽  
Metastatic Nasopharyngeal Carcinoma ◽  
Ebv Dna ◽  
Maintenance Intervention ◽  
First Line Treatment

6035 Background: The role of drug maintenance intervention in improving survival outcomes remains controversial.To investigate the safety and effect of Tegafur(S1) maintenance intervention in patients with metastatic nasopharyngeal carcinoma who benefit from the first-line treatment in a multicenter randomized controlled study, and to identify the related biological prognostic factors and guide the individualized treatment choice. Methods: Patients with metastatic nasopharyngeal carcinoma in the Fourth Affiliated Hospital of Guangxi Medical University and other cancer centers who met the inclusion criteria were randomly divided into maintenance therapy group: S1 maintenance therapy until disease progression or intolerance; Observation group: follow-up to disease progression. PFS, overall survival (OS) and adverse reactions of S1 maintenance therapy were compared between the two groups. The correlation between EBV-DNA, human serum amyloid A (SAA) and prognosis was evaluated. Results: Follow-up was conducted to May 2020, with a median follow-up of 19.8 months (6.1-51.3 months), 183 cases were evaluable (88 cases in S1 maintenance treatment group, 95 cases in observation group). Compared with the observation group, the S1 maintenance treatment group significantly increased patients' median PFS (16.2 months vs. 8.7 months, P < 0.001) and median OS (32.1 months vs. 18.2 months, P < 0.001). Reduced the risk of poor prognosis for PFS and OS (PFS: HR 0.305, 95%CI 0.211-0.441, < 0.001; OS: HR 0.363, 95%CI 0.238-0.553, P < 0.001). In the maintenance treatment group, the median S1 treatment lasted for 14 courses (4-58 courses), and the main adverse reactions were grade 1 skin pigmentation, oral mucositis, hand-foot syndrome, nausea, etc. No grade 4 toxic reaction occurred, and it was well tolerated. Compared with observation patients with negative EBV-DNA, observation patients with positive EBV-DNA had a higher risk of poor prognosis for PFS (HR 1.764, 95%CI 1.078-2.887, P = 0.024). The risk of poor prognosis in patients with positive EBV-NDA was significantly reduced by 61.1% ( < 0.001) for PFS and 65.5% (P = 0.001) for OS (P = 0.001). Compared with the observation group with stable SAA expression, S1 maintenance therapy significantly improved the prognosis of patients. Patients with continuous decline in SAA had a 61.9% lower risk of poor prognosis in PFS (P < 0.001) and a 60.2% lower risk of poor prognosis in OS (P = 0.007). Conclusions: For patients with metastatic nasopharyngeal carcinoma who benefit from first-line treatment, maintenance therapy of S1 can significantly improve the survival prognosis and is well tolerated. Patients with positive EBV-DNA and continuous decline in SAA may benefit more from maintenance intervention. Clinical trial information: ChiCTR-IOR-16007939.

scholarly journals Increased expression of PDIA3 and its association with cancer cell proliferation and poor prognosis in hepatocellular carcinoma

2016 ◽  
Vol 12 (6) ◽  
pp. 4896-4904 ◽  
Author(s):  
Hideyuki Takata ◽  
Mitsuhiro Kudo ◽  
Tetsushi Yamamoto ◽  
Junji Ueda ◽  
Kousuke Ishino ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Proliferation ◽  
Cancer Cell ◽  
Poor Prognosis ◽  
Cancer Cell Proliferation

scholarly journals OCT4 Positively Regulates Survivin Expression to Promote Cancer Cell Proliferation and Leads to Poor Prognosis in Esophageal Squamous Cell Carcinoma

PLoS ONE ◽  
2012 ◽  
Vol 7 (11) ◽  
pp. e49693 ◽  
Author(s):  
Chunguang Li ◽  
Yan Yan ◽  
Weidan Ji ◽  
Longlong Bao ◽  
Haihua Qian ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Cancer Cell ◽  
Squamous Cell ◽  
Poor Prognosis ◽  
Survivin Expression ◽  
Cancer Cell Proliferation

scholarly journals Overexpression of KIF2A is Suppressed by miR-206 and Associated with Poor Prognosis in Ovarian Cancer

2018 ◽  
Vol 50 (3) ◽  
pp. 810-822 ◽  
Author(s):  
Nan Sheng ◽  
Yun-Zhao Xu ◽  
Qing-Hua Xi ◽  
Hai-Yan Jiang ◽  
Chen-Yi Wang ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cell Proliferation ◽  
Cancer Cell ◽  
Poor Prognosis ◽  
Ovarian Cancer Cell ◽  
Expression Profiles ◽  
Annexin V ◽  
Prognostic Indicator ◽  
Luciferase Reporter ◽  
Migration And Invasion

Background/Aims: This study aimed to investigate the expression and prognostic value of kinesin family member 2A (KIF2A) and the suppression effects of microRNA-206 (miR-206) on KIF2A in ovarian cancer. Methods: Ovarian cancer tissues from patients and ovarian cancer cell lines (A2780 and SKOV3) were used in this study. miR-206 mimics and control were transiently transfected into cells. RT-qPCR was performed to detect KIF2A mRNA and miR-206 expression levels, Western blot was performed to detect KIF2A protein levels, Dual-Luciferase Reporter Assay was used to examine the inhibition effects of miR-206 on KIF2A mRNA, immunohistochemical staining was used to examine the expression of KIF2A in tissue sections. CCK-8, transwell and Annexin-V-FITC/Propidium Iodide staining with flow cytometry were used to detect the cell proliferation, migration/invasion, and apoptosis respectively. Results: Our study explored the expression profiles of KIF2A and miR-206 in the patients with ovarian cancer. We found that overexpression of KIF2A was associated with a poor prognosis in ovarian cancer. We also found that KIF2A mRNA contains two target sites for miR-206 binding and confirmed that miR-206 directly suppresses KIF2A; inhibits ovarian cancer cell proliferation, migration, and invasion; and induces apoptosis. Conclusion: The results suggest KIF2A could serve a valuable prognostic indicator in ovarian cancer and provide a rationale for treatment of ovarian cancer by targeting KIF2A via miR-206.

Sign in / Sign up

Export Citation Format

Share Document